Latest astrocytoma Stories
--Data from Ongoing Glioblastoma Dosimetry Trial Accepted for Oral Presentation at 2009 Society of Nuclear Medicine Annual Meeting -- --Over 65 Recurrent GBM Patients in Phase I and Phase II Clinical Trials Have Received Cotara to Date, with a Good Safety Profile and Longer-Term Survivors Seen in All Studies-- TUSTIN, Calif., May 28 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc.
Duke University researchers have identified a receptor on the surface of cells that may give them another avenue of attack against glioblastoma, the most common and most deadly type of brain cancer.
Schering-Plough Receives EU and US Approvals for Intravenous Formulation of Temozolomide As Well As EU Approval for Oral Temozolomide Sachet Presentation KENILWORTH, N.J., March 5 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that the European Commission and the US FDA both approved the intravenous (IV) formulation of temozolomide as an alternative to the already approved oral form of the drug.
Schering-Plough Receives CHMP Positive Opinion for TEMODAL(R) Intravenous Formulation and Oral TEMODAL Sachet Presentation -- Providing Potential New Treatment Options for EU Patients with Certain Primary Brain Tumors KENILWORTH, N.J., Dec.
Researchers from Cambridge University have pinpointed a sequence of DNA present in two-thirds of common tumors for the first time.
DUBLIN, Calif., Aug. 7 /PRNewswire-FirstCall/ -- SuperGen, Inc. , a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced that the U.S.
After Sen. Edward M. Kennedy was hospitalized on Saturday, having suffered a seizure, doctors at Massachusetts General Hospital announced a sobering diagnosis of the worst kind of brain cancer on Tuesday.
By Rodriguez, Fausto J Perry, Arie; Gutmann, David H; O'Neill, Brian Patrick; Leonard, Jeffrey; Bryant, Sandra; Giannini, Caterina Abstract There are few pathologic studies of gliomas in patients with neurofibromatosis type 1.
The Burzynski Research Institute, Inc. (OTCBB: BZYR) and the Burzynski Clinic will celebrate "30 Years of Saving Lives" during an evening gala event on October 13, 2007 at Omni Westside Hotel in Houston. The event will highlight the cancer survivors who used Dr.
- A political dynamiter.